Paul Ehrlich's magic bullet concept: 100 years of progress (Q48322740)

10 February 2018

http://europepmc.org/abstract/MED/18469827

review article

1 reference

title

Paul Ehrlich's magic bullet concept: 100 years of progress (English)

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

author name string

Klaus Strebhardt

series ordinal

1

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

Axel Ullrich

series ordinal

2

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

language of work or name

English

0 references

publication date

12 May 2008

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

published in

Nature Reviews Cancer

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

volume

8

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

issue

6

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

page(s)

473-480

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

cites work

The morphology and motility of Proteus vulgaris and other organisms cultured in the presence of penicillin

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

The initial clinical trial of nitrogen mustard

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Inter-strand crosslinking of DNA by nitrogen mustard

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

The chemistry and biochemistry of purine analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cancer genes and the pathways they control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

31 March 2020

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cancer revoked: oncogenes as therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Targeting cell cycle kinases for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cdk1 is sufficient to drive the mammalian cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Targeting polo-like kinase 1 for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Tumor inhibition by genomically integrated inducible RNAi-cassettes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Substrate competitive inhibitors of IGF-1 receptor kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Predicting benefit from anti-angiogenic agents in malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Molecular basis for sunitinib efficacy and future clinical development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Clinical and biological significance of HSP89 alpha in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Expression and roles of heat shock proteins in human breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

HSP90 and the chaperoning of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Antibody targeted drugs as cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Complement activation determines the therapeutic activity of rituximab in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cetuximab for the treatment of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Gefitinib--a novel targeted approach to treating cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Immunotoxin therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Designing immunotoxins for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Novel radiolabeled antibody conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Monoclonal antibody therapy for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Mylotarg: antibody-targeted chemotherapy comes of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Preclinical and Clinical Pharmacology of Vinca Alkaloids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Localization of the colchicine-binding site of tubulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Structure-activity relationship of aniline mustards acting against B-16 melanoma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Comparative QSAR: Toward a Deeper Understanding of Chemicobiological Interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Comprehensive survey of combinatorial library synthesis: 1999.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

High-throughput oncogene mutation profiling in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Characterizing the cancer genome in lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Expanding the repertoire of RNA interference screens for developing new anticancer drug targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

A probability-based approach for the analysis of large-scale RNAi screens.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Protein crystallization: virtual screening and optimization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Binding thermodynamics of substituted diaminopyrimidine renin inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Computer-based de novo design of drug-like molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Trastuzumab for early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Novel approaches to advanced breast cancer: bevacizumab and lapatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

ADMET--turning chemicals into drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Another look at imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Strategies to overcome resistance to targeted protein kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Rational design of inhibitors that bind to inactive kinase conformations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

A Src-like inactive conformation in the abl tyrosine kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Genetically engineered models have advantages over xenografts for preclinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

The mighty mouse: genetically engineered mouse models in cancer drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Maximizing mouse cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Biomarkers in cancer staging, prognosis and treatment selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

BAY 43-9006 inhibition of oncogenic RET mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Towards a proteome-scale map of the human protein–protein interaction network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Adapting proteostasis for disease intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

inferred from DOI database lookup

7 January 2021

based on heuristic

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC2394

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC2394

1 reference

10 February 2018

http://europepmc.org/abstract/MED/18469827

1 reference

10 February 2018